Dr.Wise AI Lung Cancer helped doctors rate lung nodule risk on CT

In the maker's trial that China's CMDE reviewed, doctors' area under the ROC curve for suspected malignant lung nodules rose from 0.7325 to 0.8397 with Dr.Wise AI Lung Cancer.

  • Not rated an organization

    The gain was measured in the maker's pre-market reader trial, and the report does not say whether the readings guided any patient's care.

Depth runs from 1, a convenience or time saved, to 5, a life or a livelihood preserved.

Status
Intended benefit.
Evidence

foundstudiedreportedclaimed

An independent regulatory document supports the benefit.

Compared with

The same doctors reading the same CT cases without the software, with imaging, thoracic surgery and pathology experts as the reference. Measured.

Without the system
Subject-level area under the ROC curve 0.7325±0.0234
With it
Subject-level area under the ROC curve 0.8397±0.0165
The system’s part
Doctors read the same cases with and without the software in a paired design, so the gains are attributed to the software. The trial was the maker's own. The report describes a deep learning module that analyzes whether nodules are benign or malignant.
Not yet checked
LimitsCosts and harmsLearns from dataLater outcome

Download data Cite Suggest a correction

Benefit type
Improved Task Accuracy
System
Dr.Wise AI Lung Cancer (肺结节CT图像辅助诊断软件)
Made by
Beijing Deepwise (北京深睿博联科技有限责任公司)
Used by
Beijing Deepwise (multi-reader trial with 400 subjects at three sites)
Where
Three trial sites that the report does not name, for a registration in China
Stage
Tested in a laboratory
Date
, when the source was published
Kind
Aggregate result
Broad benefit
Identifying Objects, Actions, and Events
Collections
Scrutiny and findings
Last revised
1 November 2026

Sources

  1. Regulatory document, by authors with no tie to the system.

    Center for Medical Device Evaluation (CMDE), National Medical Products Administration, China. 医疗器械产品注册技术审评报告：肺结节CT图像辅助诊断软件 (technical review report for the registration of lung nodule diagnosis-aid software for CT images), acceptance no. CQZ2302309, applicant 北京深睿博联科技有限责任公司. 29 September 2024. Section 三、临床评价概述 (clinical evaluation).

    AI+医生联合阅片和医生单独阅片的灵敏度组间差值及 95%CI 为 7.64%（6.13%,9.15%）
    经综合评价，认为该产品上市带来的受益大于风险，综合剩余风险可接受。

Details

AI system

Reported configuration

Release 1 (full version 1.1.0.1)

Workflow

A doctor selected each nodule on the CT image. The software combined morphological features with deep learning to flag a suspected malignancy risk for the selected nodule.

Follow-up

Conditions for replication

Nodules are 4 mm or larger on adult chest CT and are not pure ground-glass nodules. The software is not used for lung cancer screening. Trained doctors make the final judgment and do not base a clinical decision on the software alone.

Entry details

Sector

Healthcare.

Purpose

Beijing Deepwise built Dr.Wise AI Lung Cancer to tell trained doctors whether a lung nodule of 4 mm or more on adult chest CT carries a suspected risk of malignancy.

29 more questions not yet checked

model, provider, role, configuration, inputs and outputs, autonomy, human oversight, beneficiaries, reach, distribution and access, duration, every measurement question, every money question, ownership and control, dependencies, cross-border connections, geopolitical implications, replication attempts, availability, institutional decision, grounds, action and result, success criterion, every evidence question, observed or intended, alternative assessments, related entries, other identifiers, category mappings.

Cite this record

Peter H. Vartanian. (2026). Dr.Wise AI Lung Cancer helped doctors rate lung nodule risk on CT (AIBD-1063). Artificial Intelligence Benefits Database, edition of 1 November 2026. https://petervartanian.xyz/aibd/records/AIBD-1063.html (archived at https://doi.org/10.7910/DVN/AADSII, version 7.0)

BibTeX Data Field definitions